AIM: We performed a meta-analysis of the risk of selected gastrointestinal 
toxicities associated with immune checkpoint inhibitors.
PATIENTS & METHODS: Eligible studies included randomized trials of patients with 
solid tumors on ipilimumab, nivolumab, pembrolizumab, tremelimumab, pidilizumab 
and atezolizumab, describing events of diarrhea, vomiting or colitis.
RESULTS: After exclusion of ineligible studies, a total of ten clinical trials 
were considered eligible for the meta-analysis. The relative risk of all-grade 
diarrhea, vomiting and colitis was 1.64 (95% CI: 1.19-2.26; p = 0.002), 0.72 
(95% CI: 0.49-1.07; p = 0.1), 10.35 (95% CI: 5.78-18.53; p < 0.00001), 
respectively.
CONCLUSION: Our meta-analysis has demonstrated that immune checkpoint inhibitors 
are associated with a significantly increased risk of all grade and high-grade 
colitis.